18 and older, any sex, with Vitiligo. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Change From Baseline in F-VASI ScoreSecondary· Weeks 4, 8, 12, 16, 20, and 24
The mean (SD) percentage change from baseline in F-VASI scores across study time points is presented. F-VASI measures the % of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (none), 10% (only specks), 25% (pigmented area \> depigmented area), 50% (depigmented and pigmented areas equal), 75% (depigmented area \> pigmented area), 90% (specks of pigment), or 100% (no pigment). F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the value
Week 4
Group
Value
95% CI
Active IP and Active Phototherapy
-21.009
± 25.0121
Active IP and Sham Phototherapy
-7.775
± 11.8841
Vehicle and Active Phototherapy
-11.589
± 21.5439
Vehicle and Sham Phototherapy
2.857
± 6.3888
Week 8
Group
Value
95% CI
Active IP and Active Phototherapy
-57.160
± 27.3703
Active IP and Sham Phototherapy
-27.917
± 23.4974
Vehicle and Active Phototherapy
-39.570
± 27.5064
Vehicle and Sham Phototherapy
-16.667
± 23.5702
Week 12
Group
Value
95% CI
Active IP and Active Phototherapy
-62.963
± NA
Active IP and Sham Phototherapy
-54.157
± 16.7882
Vehicle and Active Phototherapy
-33.333
± NA
Week 16
Group
Value
95% CI
Active IP and Sham Phototherapy
-10.100
± 55.6893
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to ~22 weeks.
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04378569 — Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema
· Phase 1, PHASE2
· completed
Other recruiting trials for Vitiligo
Currently open trials in the same condition.
NCT07153666 — A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
· recruiting
NCT07267273 — Betamethasone Phonophoresis For Vitiligo
· NA
· recruiting
NCT07232238 — TRPM2 Gene Polymorphism, NLRP3 Inflammasome Expression in Vitiligo Patients
· active not recruiting
NCT07532330 — Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo
· NA
· active not recruiting
NCT07357870 — A Proof of Concept, Phase 1 Study of CGB-600 for the Topical Treatment of Non-Segmented Facial Vitiligo
· Phase 1
· recruiting
Other Arcutis Biotherapeutics, Inc. trials
Trials by the same sponsor.
NCT06998056 — Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis
· Phase 2
· completed
NCT05028582 — Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
· Phase 3
· completed
NCT04973228 — Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
· Phase 3
· completed
NCT04845620 — Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (Integument-PED)
· Phase 3
· completed
NCT04746911 — Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arcutis Biotherapeutics, Inc.
Last refreshed: 12 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04811131.